Clinical trials: For Treatment of Chronic Hepatitis B Virus Infection
Chronic Hepatitis B, HIV Infections
Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients
The efficacy of pegylated interferons in the treatment of chronic hepatitis B has shown superior results to standard of care in patients only infected with hepatitis B.
- Trial name
- NCT00221286
- Testing
- pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy
- Where
- 5 sites in Germany
- Volunteers
- 2 people
- Sponsor
- University Hospital, Bonn
Chronic Hep B
Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary Care
This is a retrospective-prospective longitudinal cohort study, with analyses performed before and after introduction of the pathway, and comparisons made to unexposed controls.
- Trial name
- NCT04904900
- Where
- Hong Kong
- Volunteers
- 3,300 people
- Sponsor
- Chinese University of Hong Kong
Hepatitis B, Chronic
Linkage to Care and Treatment of Chronic HBV Patients
Chronic hepatitis B remains the leading cause of liver related mortality and morbidity globally and locally. Countries have been formulating initiatives to meet the WHO target of eliminating viral hepatitis by 2030.
- Trial name
- HBV (NCT06658678)
- Testing
- Receiving an educational intervention
- Where
- Hong Kong
- Volunteers
- 803 people
- Sponsor
- The University of Hong Kong
Hepatitis B, Chronic, Cirrhosis
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
This 36-month open-label study of adefovir dipivoxil investigates the clinical benefits of the therapy in chronic hepatitis B patients with advanced fibrosis or cirrhosis confirmed with biopsy.
- Conditions
- Hepatitis B, Chronic, Cirrhosis, Fibrosis, Chronic Hepatitis B
- Trial name
- NCT00347009
- Testing
- adefovir dipivoxil
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 155 people
- Sponsor
- GlaxoSmithKline
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B
Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment.
- Trial name
- EPCP (NCT05922306)
- Testing
- PEGylated recombinant human interferon alpha-2b injection
- Where
- China
- Volunteers
- 1,084 people
- Sponsor
- Anhui Medical University
Hepatitis B
Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
The purpose of this study is to evaluate the efficacy and safety of generic entecavir monotherapy or in combination with adefovir for chronic hepatitis B patients with inadequate response to NUC therapy
- Trial name
- NCT01341743
- Testing
- Entecavir, Entecavir, Adefovir
- Where
- 16 sites in China
- Volunteers
- 360 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis C, Chronic Hepatitis B
4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
Open-label studies, anecdotal reports, and in vitro scientific research indicate that 4-methylumbelliferone (active ingredient of the dietary supplement Heparvit®) may prevent and reverse the symptoms and complications of chronic…
- Trial name
- NCT00225537
- Testing
- 4-Methylumbelliferone (Heparvit®)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- MTmedical Institute of Health
HIV Infections, Chronic Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection
This study will evaluate the safety and effectiveness of adefovir plus lamivudine for chronic hepatitis B infection in people with and without HIV infection.
- Trial name
- NCT00023153
- Testing
- Adefovir Dipivoxil
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis b
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients
A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are enrolled. All the patients will receive original antiviral treatment for the following 10 years.
- Trial name
- NCT03777969
- Where
- 7 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
Chronic Hepatitis b, Immunotherapy
Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults
Establish a study cohort of adult chronic hepatitis B antiviral treatment based on the principle of responseguidedtreatment (RGT) corresponding to the child cohort, analyze the clinical cure factors of IC and IT stage adults…
- Trial name
- NCT06777173
- Testing
- Peg interferon alfa-2b
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Ditan Hospital
Adoptive Treatment for Hepatitis B With γδT Cells
"Treatment of Active HBV With γδT Cells" Clinical Trial Protocol
To evaluate the safety and anti-HBV efficacy of γδT cells.
- Trial name
- NCT03113058
- Testing
- Adoptive transfer of γδT cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jinan University Guangzhou
Hepatitis B, Chronic
A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.
- Trial name
- NCT00651209
- Testing
- Tenofovir
- Where
- 4 sites in Argentina, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
Performance of Novel Simplified Score for Chronic Hepatitis B Treatment Eligibility in Thailand
International and national guideline for chronic hepatitis B (HBV) infection treatment recommend initiated antiviral in high HBV viral loads patients with significant liver inflammation and significant liver fibrosis.
- Trial name
- NCT05295914
- Testing
- TREAT-B score
- Where
- Thailand
- Volunteers
- 600 people
- Sponsor
- Mahidol University
Chronic Hepatitis B
Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
The purpose of the study is to investigate the safety and the antiviral activity of two doses of LB80380 for 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to entecavir 0.5 mg.
- Trial name
- NCT01026610
- Testing
- LB80380 90 mg, LB80380 150 mg, entecavir 0.5 mg
- Where
- 10 sites in China, South Korea
- Volunteers
- 115 people
- Sponsor
- LG Life Sciences
Chronic Hepatitis B, Inadequate Response
Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
The purpose of this study is to compare the long-term efficacy and safety of entecavir 1.0 mg/d + adefovir 10 mg/d with entecavir 0.5 mg/d + adefovir 10 mg/d for chronic hepatitis B patients with inadequate response to NUC therapy
- Conditions
- Chronic Hepatitis B, Inadequate Response, Nucleos(t)Ide Analogues Treatment
- Trial name
- Dragon-Ex (NCT01829685)
- Testing
- Entecavir, Adefovir
- Where
- 16 sites in China
- Volunteers
- 360 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis B
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
- Trial name
- NCT03780543
- Testing
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 92 people
- Sponsor
- Assembly Biosciences
Hepatitis B, Chronic
Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy
To determine the optimal time for the Tenofovir treatment of anti-Hepatitis B Virus (HBV) during the pregnancy among women with chronic HBV infection and high HBV DNA load.
- Trial name
- NCT02510963
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis B
Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B
Hepatitis B virus (HBV) causes a wide spectrum of liver diseases, such as fulminant or acute hepatitis, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT00275938
- Testing
- interferon alpha 2b plus ribavirin
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
HBeAg-positive Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940471
- Testing
- TAF, TDF
- Where
- 160 sites in United States, Australia and 17 more
- Volunteers
- 875 people
- Sponsor
- Gilead Sciences